Yaron Naos - Protalix Biotherapeutics Senior Vice President - Operations
| PLX Stock | USD 1.20 0.02 1.69% |
President
Mr. Yaron Naos is Senior Vice President Operations of the Company. He joined Protalix Ltd. in 2004 as Senior Director, Operations, and, since 2008, has served as the Companys Vice President for Production. He has a wealth of handson experience and knowledge in the field of pharmaceutical development since 2018.
| Age | 60 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | Science Park, Karmiel, Israel, 2161401 |
| Phone | 972 4 902 8100 |
| Web | https://www.protalix.com |
Protalix Biotherapeutics Management Efficiency
The company has Return on Asset of 0.0933 % which means that on every $100 spent on assets, it made $0.0933 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.725 %, implying that it generated $0.725 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.28 in 2024, whereas Return On Equity is likely to drop 0.24 in 2024. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.10 in 2024, whereas Total Assets are likely to drop slightly above 51 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Melissa Ashlock | aTyr Pharma | 66 | |
| Theresa McNeely | Akebia Ther | N/A | |
| Praveen Tyle | Lexicon Pharmaceuticals | 57 | |
| Michele Trucksis | Seres Therapeutics | 64 | |
| Alyssa Wyant | PDS Biotechnology Corp | 42 | |
| Wael Hashad | Seres Therapeutics | N/A | |
| Thomas DesRosier | Seres Therapeutics | 63 | |
| Grove Matsuoka | aTyr Pharma | 57 | |
| Jason Coloma | Corvus Pharmaceuticals | 40 | |
| Les Tari | Cidara Therapeutics | N/A | |
| Mehrdad Mobasher | Corvus Pharmaceuticals | N/A | |
| Carmen Betancourt | Cidara Therapeutics | N/A | |
| Jeffrey Stein | Cidara Therapeutics | 69 | |
| Kiernan Seth | Lexicon Pharmaceuticals | N/A | |
| Stephen Machatha | Aldeyra | 47 | |
| Holly Chrzanowski | aTyr Pharma | 48 | |
| Dell Faulkingham | Akebia Ther | N/A | |
| David King | aTyr Pharma | 65 | |
| Pablo Lapuerta | Lexicon Pharmaceuticals | 54 | |
| John McKew | aTyr Pharma | 50 | |
| Fred Ramsdell | aTyr Pharma | 53 | |
Management Performance
| Return On Equity | 0.73 | ||||
| Return On Asset | 0.0933 |
Protalix Biotherapeutics Leadership Team
Elected by the shareholders, the Protalix Biotherapeutics' board of directors comprises two types of representatives: Protalix Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protalix. The board's role is to monitor Protalix Biotherapeutics' management team and ensure that shareholders' interests are well served. Protalix Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protalix Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Kornberg, Independent Director | ||
| Eyal MBA, CFO, VP | ||
| Yoseph Shaaltiel, Founder and Executive VP of RandD | ||
| Shlomo Yanai, Chairman of the Board | ||
| Yaron Naos, Senior Vice President - Operations | ||
| Amos BarShalev, Independent Director | ||
| Tzvi Palash, COO | ||
| Yael Fellous, Vice Resources | ||
| Dror Bashan, President CEO | ||
| Aharon Schwartz, Independent Director | ||
| Zeev Bronfeld, Independent Interim Chairman of the Board | ||
| Einat Almon, Sr. VP of Product Devel. | ||
| Yossi Maimon, CFO, Vice President Treasurer, Secretary | ||
| David Granot, Independent Director | ||
| Marcy Nanus, Investor Contact | ||
| Moshe Manor, CEO and President and Director | ||
| Yodfat Buchris, Independent Director |
Protalix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protalix Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.73 | ||||
| Return On Asset | 0.0933 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 67.92 M | ||||
| Shares Outstanding | 73.05 M | ||||
| Shares Owned By Insiders | 9.76 % | ||||
| Shares Owned By Institutions | 13.90 % | ||||
| Number Of Shares Shorted | 6.46 M | ||||
| Price To Earning | (1.23) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protalix Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protalix Biotherapeutics' short interest history, or implied volatility extrapolated from Protalix Biotherapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.